Literature DB >> 25872332

The role of mTOR signaling pathway in premalignant and malignant cervical lesions.

M Andrikopoulou, N Salakos, E Deligeoroglou, A Pafiti, I Boutas, N Nikitakis, A Sklavounou, G Creatsas.   

Abstract

PURPOSE OF THE STUDY: Aberrant activation of the Akt/mTOR/pS6 signaling pathway has been identified in various types of cancer and is under investigation in cervical cancer. The purpose of this study was to assess the expression of the phosphorylated/activated forms of Akt (upstream molecule), 4E-BP1 and pS6 (downstream molecules) in biopsy samples of cervical low grade squamous intraepithelial lesions (LSIL), high grade squamous intraepithelial lesions (HSIL), and squamous cell carcinoma (Ca) compared to normal cervical epithelium.
MATERIAL AND METHODS: The study included 38 cases diagnosed as LSIL, 31 cases as HSIL, 29 cases as Ca, and eight control cases from normal cervix. Immunohistochemistry was used to assess the expression of pAkt, p4E-BP1 and pS6.
RESULTS: Statistical analysis revealed significant differences between HSIL and Ca groups compared to controls regarding intensity, positivity, and total scores for all three molecules (p < 0.001). A trend for higher expression with increasing grade of dysplasia was demonstrated.
CONCLUSION: These results strongly support the view that the mTOR signaling pathway is involved in cervical carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25872332

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  1 in total

1.  Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature.

Authors:  Mounsif Azizi; Dominic H Tang; Daniel Verduzco; Charles C Peyton; Juan Chipollini; Zhigang Yuan; Braydon J Schaible; Jun-Min Zhou; Peter A Johnstone; Anna Giuliano; Jasreman Dhillon; Philippe E Spiess
Journal:  Clin Genitourin Cancer       Date:  2018-09-22       Impact factor: 3.121

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.